Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform you that the Board of Directors of ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivanta Industries' board approved its Q1 FY26 unaudited standalone and consolidated financial results on 13 August 2025, along with a clean limited review report from auditors GMCA & Co. Standalone revenue from operations jumped to Rs 1,056.05 lakhs from Rs 298.74 lakhs in Q1 FY25 (over 3.5x growth), while consolidated revenue surged to Rs 7,588.50 lakhs from Rs 298.74 lakhs, driven by cost of materials consumed of Rs 6,493.29 lakhs in the consolidated books (linked to the new subsidiary Trinity Ganesh and JV CKIM Pharma). Standalone profit after tax rose to Rs 32.42 lakhs (EPS Rs 0.03) versus Rs 26.16 lakhs (EPS Rs 0.02) a year ago, and consolidated PAT doubled to Rs 53.48 lakhs (EPS Rs 0.04). This marks a turnaround from FY25 when the company reported standalone and consolidated losses of Rs 159.67 lakhs and Rs 165.21 lakhs respectively.
A sharp rebound in top line and a return to profitability after a loss-making FY25 is a positive signal for shareholders, though investors should note that consolidated revenue includes a large cost of materials line, indicating a trading/low-margin business mix rather than pure value addition. The clean auditor report with no qualifications removes an immediate overhang on the stock.